The significant guidance cut and delayed cash-flow breakeven suggest the business is in a correction phase. Watch for further revenue shortfalls in H2 2026 and clinical utility study results/FDA decision on LucentAD Complete as potential catalysts. The new commercial leadership has not yet proven results.
Price Chart
Executive Summary
Quanterix Q2 2026 revenue of $32.9M missed consensus estimates of $37.5M by 12.3%, driven by execution challenges and market softness. The company slashed full-year 2026 guidance to $142-148M from $169-174M, recorded a $26.9M goodwill impairment, and pushed cash-flow breakeven to 2027.
Key Financial Metrics
Key Facts
- Revenue of $32.9M missed the $37.5M consensus estimate by 12.3%
- GAAP gross margin fell to 38.5% from 40.9% a year ago
- Net loss widened to $48.9M vs $30.0M in Q2 2025, including a $26.9M goodwill impairment
- EPS of ($1.04) per share on 47.2M shares, versus consensus of ($0.41) on a different share count — GAAP EPS not directly comparable to consensus
- Full-year 2026 revenue guidance slashed to $142-148M from $169-174M
- Cash-flow breakeven pushed to 2027 from H2 2026; year-end cash forecast lowered to ~$80M from ~$100M
- Pro-forma revenue (including Akoya pre-acquisition) declined 23% year-over-year
- Completed ERP integration and realized $85M in annualized cost synergies from Akoya acquisition
- Appointed Jim Gute as Chief Commercial Officer; named other senior leaders
Financial Impact
Revenue guidance reduced by ~16% at midpoint ($145M vs $171.5M prior midpoint), implying $10M+ in lost revenue vs prior expectations. Cash balance expected to decline to ~$80M by year-end 2026 from $96.9M.
Risk Factors
- Continued revenue shortfall from execution challenges and weak academic/pharma end markets
- Cash burn could accelerate if revenue does not recover, potentially requiring dilutive financing
- Failure to achieve 2027 cash-flow breakeven target
- Goodwill impairment signals potential for further impairments on remaining goodwill
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001503274-26-000035 |
| Exhibit: ex993-qtrxx20260630.htm | 0001503274-26-000035 |
| Document: q2-26earningspresentatio.htm | 0001503274-26-000035 |
| Document: qtrx-20260810.htm | 0001503274-26-000035 |
| Document: 0001503274-26-000035-index-headers.html | 0001503274-26-000035 |
| Document: 0001503274-26-000035-index.html | 0001503274-26-000035 |
| Document: 0001503274-26-000035.txt | 0001503274-26-000035 |
| 8-K Data (Synthetic) | 0001503274-26-000035 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $2.42 $2.73 | ▼ −12.81% | ▼ −13.72% | $3.41 (−40.91%) |
Jun 17, 2026 15w ago | Institutional Cluster | $2.88 $3.96 | ▲ +37.50% | ▲ +36.18% | $3.41 (+18.40%) |
Jun 9, 2026 16w ago | 8-K | $3.09 $4.00 | ▲ +29.45% | ▲ +28.00% | $3.41 (+10.36%) |
May 26, 2026 18w ago | 8-K | $2.65 $3.76 | ▲ +41.89% | ▲ +43.79% | $3.41 (+28.68%) |
May 8, 2026 21w ago | DEFA14A | $2.80 $3.09 | ▲ +10.36% | ▲ +10.66% | $3.41 (+21.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access